{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-25-000062","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.045842+00:00","generated_at":"2026-05-16T23:24:09.673875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96","bullets":["Net revenues of $191.8M, flat YoY vs $191.2M.","GAAP net income of $17.4M ($0.37 diluted EPS) vs $40.4M ($0.78) in Q3 2024.","Adjusted non-GAAP net income $44.7M ($0.93 diluted EPS) vs $49.6M ($0.96).","BAQSIMI revenue grew 14% YoY; FDA approval and launch of iron sucrose injection noted.","Nine-month 2025 GAAP net income $73.7M ($1.52 EPS) vs $121.6M ($2.32) prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-25-000062","json":"https://secwatch.observer/filing/0001297184-25-000062.json","markdown":"https://secwatch.observer/filing/0001297184-25-000062.md","text":"https://secwatch.observer/filing/0001297184-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/0001297184-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000062/amph-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:24:09.673875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}